Chiron acquires rights to Cerubidine from Wyeth-Ayerst.EMERYVILLE, Calif.--(BUSINESS WIRE)--March 27, 1995--Chiron Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR CHIR Chiricahua National Monument (US National Park Service) ) announced Monday that its joint-venture business with Ben Venue Laboratories of Bedford, Ohio, has purchased exclusive rights to Cerubidine (daunorubicin hydrochloride daunorubicin hydrochloride Warning - Hazardous drug! Cerubidine Pharmacologic class: Anthracycline glycoside Therapeutic class: Antibiotic antineoplastic ) for injection, a chemotherapeutic product for treatment of certain leukemias, from Wyeth-Ayerst Laboratories, a division of American Home Products Corp. Cerubidine will be sold and distributed by Chiron Therapeutics, and manufactured by Ben Venue Laboratories. Chiron Therapeutics and Ben Venue already have been licensed by the U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to manufacture and sell daunorubicin daunorubicin /dau·no·ru·bi·cin/ (daw?no-roo´bi-sin) an anthracycline (q.v.) antibiotic used as an antineoplastic; administered as the hydrochloride salt or as a liposome-encapsulated preparation of the citrate salt. , and have produced and inventoried significant quantities in anticipation of their market entry. Under terms of the agreement, Wyeth-Ayerst will assign all of its trademark and technology rights with respect to Cerubidine to the venture, and will provide the venture with its customer lists. Financial terms of the agreement were not disclosed. "As one of the mainstay therapies for leukemia, Cerubidine represents a significant addition to Chiron's expanding line of oncology products that includes Proleukin and Aredia," said Edward Kenney, vice president marketing and sales of Chiron Therapeutics. "We will build upon Wyeth-Ayerst's long-standing supply relationships by continuing to provide customers with daunorubicin under the Cerubidine brand name. We expect a seamless transition in the marketplace." Wyeth-Ayerst is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines, infant nutritionals and generic pharmaceuticals. American Home Products Corp. ranks among the top three companies in the world in sales of pharmaceuticals and health-care products. It is also a leader in agricultural products, animal health care, medical devices and food products. Chiron Therapeutics is a business unit of Chiron Corp., a biotechnology company headquartered in Emeryville, near San Francisco. In addition to marketing a line of chemotherapeutic products for its joint venture business with Ben Venue, Chiron Therapeutics markets Proleukin (aldesleukin), the first treatment for metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. , in the United States and Europe. Chiron Therapeutics also promotes Aredia (pamidronate disodium) for injection for the treatment of hypercalcemia of malignancy hypercalcemia of malignancy A clinical complex, 50% of which results from hypersecretion of parathyroid hormone-related protein–PTHRP, aka parathyroid hormone-related peptide; HCM may result from either direct replacement–eg, in lympho- and and Paget's disease. CONTACT: Chiron Corp., Emeryville Larry Kurtz, 510/601-2476 Kimberly Kraemer, 510/601-2412 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion